The TrkB agonist 7,8‐DHF has recently gained attention as being advantageous in a variety of age‐related conditions including stroke, depression, memory and learning, traumatic brain injury, Rett syndrome, Amyotrophic Lateral Sclerosis, and Parkinson's Disease (Obianyo and Ye 2013; Jang et al. This evidence concerns the gene NTRK2 and depressive symptom measurement.